Health

Cancer Drug Prices Cut: NPPA Lowers MRP of 1,364 Formulations

By Editorial Staff ·
Graphic on NPPA cutting prices of anti-cancer medicines in India

Cancer patients in India are now paying far less for many essential medicines. Revised maximum retail prices (MRPs) for 1,364 anti-cancer formulations came into force across the country on Monday, November 9, 2026. The cuts follow a decision by the National Pharmaceutical Pricing Authority (NPPA) to cap trade margins on 137 non-scheduled cancer drugs at 30%. Some brands have become cheaper by more than 90%, and the government estimates patients will save about Rs 3,540 crore every year.

Why Cancer Medicines Were So Expensive

The price a patient pays at a chemist counter includes the margins taken by distributors, stockists and retailers along the supply chain. For many cancer drugs, these margins had grown very large. A medicine that left the factory at a modest price could reach the patient at several times that amount.

The NPPA, which works under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilisers, targeted these “excessive trade margins in the distribution and retail channels”, as noted in an All India Radio report on the October 17 decision. Non-scheduled drugs are those outside the National List of Essential Medicines, so their prices are not directly fixed by the government. Capping the margin is the tool used to bring them down.

The move followed recommendations from an expert committee set up by the Directorate General of Health Services under the Union Health Ministry. It is backed by notification SO 5690 (E), dated October 17, 2026, which stays in force until further notice.

How Big the Price Cuts Are

By November 8, a total of 85 pharmaceutical companies had reported revised prices to the NPPA. The numbers show that the impact is wide.

Key highlights

  • 1,364 anti-cancer formulations now carry revised MRPs
  • 121 distinct drugs are covered in the reported list
  • 137 non-scheduled anti-cancer medicines fall under the 30% trade margin cap
  • 679 brands cut prices by more than 50%
  • 96.45% was the largest single reduction
  • Rs 3,540.38 crore is the estimated yearly saving for patients
  • 10 to 15 of the identified drugs are not yet sold in India and will come under the cap once launched

Examples of Old and New Prices

Reports based on data released by the ministry list several commonly used therapies for breast, prostate, lung, colon, ovarian and cervical cancers, as well as blood cancers. A few examples:

Medicine (brand) Old MRP (Rs) New MRP (Rs)
Palbociclib 125 mg (Palbopro), for breast cancer 40,421.33 2,720.00
Abiraterone 250 mg (Abirone), for prostate cancer 41,250.00 3,218.23
Bevacizumab 100 mg (Bryxta) 25,995.00 3,318.00
Denosumab 60 mg (DenOsteoRel) 24,955.00 6,240.00
Azacitidine 100 mg (Azadual) 4,852.03 1,207.80
Pertuzumab 420 mg (Lupiher 2) 83,520.00 37,358.35

Not every brand fell by the same amount. Some pertuzumab brands, for example, dropped by less than a third, because their existing margins were lower to begin with. Patients on long courses of oral targeted therapy, where one strip can cost tens of thousands of rupees, are likely to see the largest monthly relief.

Not the First Time: The 2019 Pilot

The government first tried this approach in 2019, when it capped trade margins on 42 anti-cancer drugs at 30%. That pilot led to MRP cuts of up to 90% on 526 brands. The 2026 exercise is more than three times larger in the number of drugs covered. Manufacturers can still apply for annual price revisions under Paragraph 20(1) of the Drugs (Prices Control) Order, 2013, as long as they stay within the 30% margin limit.

The decision also came in the same week as other health news on the site, including the WHO’s El Nino health emergency plan.

What Patients and Families Should Check

The government has said chemists and hospital pharmacies cannot charge more than the revised MRP, and that strict action will follow if they do. Companies must publish the new prices in newspapers and on their websites, and share them with retailers and hospitals. State drug controllers will monitor compliance.

Patients can take these simple steps:

  1. Check the pack. The revised MRP should be printed on the medicine.
  2. Verify online. Use the Pharma Sahi Daam app or the NPPA website to confirm the correct price.
  3. Keep the bill. A purchase invoice is needed as proof if you were overcharged.
  4. Complain if needed. Use the Pharma Jan Samadhan portal or call the NPPA helpline at 1800-111-255. Keep the prescription and medicine details ready.

Hospitals, pharmacy dealers and medical institutions are also required to display updated price lists on their premises and websites.

What It Means for Cancer Care Costs

For many Indian families, medicines are a large part of the cost of cancer care, especially for patients who take targeted therapy for months or years. A drop of several thousand rupees per strip can decide whether a family continues a full course of treatment or stops early.

The ministry has called the step “an important step taken by the Government” to improve affordability. The real test now is enforcement at the chemist counter, particularly in smaller towns, where patients may not know that prices have changed. Families should ask for the revised MRP and report any overcharging.

This article is for general information only and is not medical or professional advice. Please consult your doctor before making any change to treatment.

More Health News